Solving Pharma’s Data Silo Problem: Why a Linkable Data Infrastructure is Good for Biopharma and Good for Patients

Each year, pharmaceutical companies spend billions of dollars developing therapies that can improve patient outcomes. Much of that investment goes towards the generation and procurement of data: designing carefully controlled clinical trials; buying data to understand the market and generate real-world evidence; and managing hundreds of researchers, analysts and consultants to make sense of it.

Despite investing heavily in data, pharma companies are limited by the basic problem of not being able to connect the data they’ve amassed.